Copyright
©The Author(s) 2023.
World J Hepatol. Apr 27, 2023; 15(4): 554-563
Published online Apr 27, 2023. doi: 10.4254/wjh.v15.i4.554
Published online Apr 27, 2023. doi: 10.4254/wjh.v15.i4.554
Table 3 Outcomes of liver transplant for hepatocellular carcinoma, n (%)
| Variable | COVID, n = 518 | Pre COVID, n = 675 | Pvalue | |
| Month | March | 68 (13) | 132 (20) | 0.008 |
| April | 86 (17) | 123 (18) | ||
| May | 108 (21) | 97 (14) | ||
| June | 78 (15) | 95 (14) | ||
| July | 84 (16) | 99 (15) | ||
| August | 94 (18) | 129 (19) | ||
| Distance from donor hospital, miles, median (IQR) | 88 (23, 188) | 50 (8, 164) | < 0.001 | |
| Cold ischemia time, hours median (IQR) | 5.87 (4.71, 7.07) | 5.78 (4.65, 7.12) | 0.84 | |
| Acute rejection before discharge | 17 (3.3) | 11(1.6) | 0.061 | |
| Treatment rejection within 6 month | 27 (6.4) | 38 (6.6) | 0.88 | |
| Treatment rejection within 1 year | 35 (8.4) | 45 (8.4) | 0.99 | |
| Length of stay, days median (IQR) | 8 (6, 11) | 8 (6, 12) | 0.60 | |
| Survival rate | ||||
| 90-day overall survival | 97.7 | 97.9 | 0.95 | |
| 180-day overall survival | 94.7 | 97.0 | 0.048 | |
| Two-year overall survival | 86.5 | 91.7 | 0.0063 | |
| 90 day graft survival | 96.1 | 96.7 | 0.71 | |
| 180 day graft survival | 92.8 | 95.7 | 0.035 | |
| Two-year graft survival | 84.5 | 89.6 | 0.014 | |
- Citation: Lee IS, Okumura K, Misawa R, Sogawa H, Veillette G, John D, Diflo T, Nishida S, Dhand A. Inferior outcomes of liver transplantation for hepatocellular carcinoma during early-COVID-19 pandemic in the United States. World J Hepatol 2023; 15(4): 554-563
- URL: https://www.wjgnet.com/1948-5182/full/v15/i4/554.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i4.554